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In resourced settings with access to highly active antire-
troviral therapy (HAART), perinatally acquired HIV-1
infection has become a chronic disease of childhood.
Reduced mortality due to HAART, combined with high
uptake of antenatal HIV testing and a marked reduction
in rates of mother-to-child transmission has resulted in
significant increases in the average age of paediatric
cohorts in these regions and hence increasing numbers
of children born with HIV are surviving to early adult-
hood and completing the process of transition from pae-
diatric to adult services. Advances in antiretroviral
therapy, reductions in pill burdens and drug side effects,
new classes and new drugs within existing antiretroviral
classes offer enormous benefits, although serious issues
around adherence during adolescence continue. Ques-
tions persist around the optimal timing and sequencing
of antiretroviral agents to maintain future treatment
options, particularly with global recommendations for
the earlier initiation of therapy across the paediatric age
range. The longer term impact of exposure to HIV and
antiretroviral therapy throughout childhood are becom-
ing apparent, with growing concern over neurocognitive,
cardiovascular, renal and bone health requiring further
elucidation. Adolescents living with perinatally acquired
HIV have additional psychosocial issues including the
impact of HIV on other family members, roles as young
carers, experience of parental and sibling bereavement,
and live with a disease that is potentially transmissible
to future sexual partners before they themselves have
had sex. Increasing numbers of young women born
themselves with HIV are becoming sexually active and
having uninfected infants of their own and the long
term outcomes for the next generation require monitor-
ing. The benefits of HAART far outweigh the potential
risks and the careful follow up of this early perinatal
cohort as they progress through adulthood will hopefully
aid the future management of the growing numbers of
adolescents surviving worldwide as access to therapy
improves.
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